AC Immune SA

AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases. AC Immune SA develops therapeutic and diagnostic products designed to address disorders linked to protein misfolding, with a current emphasis on Alzheimer’s disease, Parkinson’s disease, ALS, and selected rare neurodegenerative conditions. Its work centers on proprietary technology platforms that support the discovery of antibodies, small molecules, vaccines, and imaging agents intended for early detection, treatment, and prevention. The company’s pipeline spans both therapeutic and diagnostic programs, reflecting a dual approach to understanding disease biology and creating targeted interventions. AC Immune SA also collaborates with pharmaceutical and research partners to advance its programs across neurodegenerative markets. Headquartered in Lausanne, Switzerland, AC Immune SA plays a specialized role in the biotechnology sector by developing tools and treatments aimed at some of the most complex and underserved diseases of the nervous system.